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demographic size of ACs) were calculated for selected tariffs. RESULTS: We observed 
lack of consistency in structure and contents of tariff lists and in tariff levels, as 
exempliﬁ ed by: different categorization of services; incomplete listing of services; dif-
ferent terminologies; different levels of detail for common services (e.g. MRI: 2–127 
options by body area and/or complexity); wide ranges of tariffs for most items (e.g. 
specialist visit: c56–c191, general ward per diem: c82–c569, simple MRI: c120–c634). 
Wide variations were also observed for other diagnostic investigations, (non-)surgical 
procedures, laboratory tests and DRGs. CONCLUSIONS: Wide ranges in tariffs for 
health resources commonly used in economic evaluations were identiﬁ ed across ACs, 
with a difference between minimum and maximum values of at least factor 2. There 
exists no evidence on how tariffs are calculated and if they reﬂ ect real cost. Available 
AC tariffs should be used with caution and a simple or weighted average across AC 
tariff lists may be used as proxies for nation-wide costs. Elaboration of a nation-wide 
list would avoid possible bias from analysts in the selection of cost values to obtain 
given results.
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OBJECTIVES: We examined the association between economic evaluation studies 
performed in Spain in 1983–2008 and the burden of disease in the population. 
METHODS: Cross-sectional observational study. Electronic databases (Pubmed/
MEDLINE, SCOPUS, ISI Web of Knowledge, CRD, IME, IBECS) and reports from 
public agencies were systematically reviewed. Inclusion and exclusion criteria and a 
set of variables were deﬁ ned to analyze the characteristics of the papers selected. Using 
the Global Burden of Disease (GBD) study classiﬁ cation the following measures were 
calculated: years of life lost (YLLs), years lived with disability (YLDs), disability-
adjusted life-years (DALYs), and mortality by cause. Correlation and linear regression 
models were used. RESULTS: Cardiovascular diseases (15.7%), infectious and para-
sitic diseases (15.3%), and malignant neoplasms (13.2%) were the conditions most 
commonly addressed. Accidents and injuries, congenital anomalies, oral conditions, 
nutritional deﬁ ciencies and other neoplasms were the categories with a lowest number 
of studies (0.6% from the total for each of them). The disease sub-categories most 
prevalent in the studies were lower respiratory infections (5.7%), ischemic heart 
disease (5.7%), hepatitis B and C (3.3%) and HIV/AIDS (3.1%). For GBD categories 
(n = 20), a correlation was seen with: mortality 0.67 (p = 0.001), DALYs 0.63 (p = 
0.003), YLLs 0.54 (p = 0.014), and YLDs 0.51 (p = 0.018). By diseases sub-categories 
(n = 51), the correlations were low and non statistically signiﬁ cant. CONCLUSIONS: 
There is a mild-moderate association of economic evaluations with the main causes 
of burden of disease. For some conditions, the data show over or under-representation 
of studies related to their burden generated. The burden of disease is a criterion that, 
in combination with efﬁ ciency and equity, would allow to set recommendations to 
guide debates on health research priority setting.
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BACKGROUND: The major focus of the history of economic thought has been 
devoted to deﬁ ning a scientiﬁ c theory of value. An even harder task entails formulating 
a theory of intertemporal value. Work on this theory date back to the birth of modern 
economic thought. For example, some authors have argued that an intertemporal 
utility based theory of value involves the explanation of a quantity which can be 
directly observed and measured in terms of a quantity which cannot. Major current 
debates on discounting therefore surround the need for a scientiﬁ c deﬁ nition and the 
ethics towards intergenerational justice. OBJECTIVES: We investigate how several 
current issues in discounting might be irrelevant by adopting a Neo-Ricardian view 
of intertemporal value by recursively applying valuation of a commodity from value 
of input commodities, thereby simplifying to the Physiocratic School. We further 
investigate how our empirical model might be extended to current utilitarian philoso-
phy. METHODS: We adopt a Srafﬁ an approach and devise a pure value-growth 
matrix that relies only on empirical data. We ﬁ rst derive a 2 × 2 matrix and then a 3 
× 3 matrix. We use health effects, income and a third externality for the derivations. 
RESULTS: It seems that the Neo-Riccardian approach provides the necessary require-
ments towards satisfying a scientiﬁ c deﬁ nition of intertemporal value and allows 
extension of the classical framework of health and wealth with a 3rd dimension of 
externalities. Furthermore, by redeﬁ ning the pure growth term in our 2 × 2 matrix 
with the Ramsey discount rate, our results simplify to current economic theory. 
CONCLUSIONS: Although modern economic theory explains value from a utilitarian 
viewpoint, it seems that it lacks robustness in explaining intertemporal value. There-
fore, we suggest that the Srafﬁ an School of economic thought should also be consid-
ered when attempting to formulate a discount rate for health effects, within a concept 
of sustainable growth.
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OBJECTIVE: To verify the reliability of the methodology used in the manufacturers’ 
Budget Impact Analyses (BIAs) submitted in reimbursement dossier to Polish HTA 
Agency, we compared public payer (National Health Fund—NHF) actual expendi-
tures on selected drugs with their estimated costs. METHODS: BIAs of medicines 
reimbursed for at least one year and assessed previously in Agency were selected for 
the analysis. The BI estimated by the manufacturer in the ﬁ rst year after product’s 
introduction to reimbursement was used. Estimated size of target population was 
compared with the actual one. The actual data was obtained from the NHF. BIAs for 
selected medicines were critically appraised to determine any variables that may have 
affected its reliability. RESULTS: 20 BIAs met inclusion criteria and were included 
into the study. Forty-ﬁ ve percent (9/20) of the BI expenditures were underestimated. 
Median and mean difference between actual and estimated expenditure were 17,22% 
and 30,25% respectively. The overestimation was found in 55% BIAs (11/20); median 
= 262,26%, mean difference = 2267,25%. Population size was underestimated in 65% 
(13/20) of the BIAs. Median and mean difference between actual and estimated popu-
lation were 25,61% and 33,93% respectively. Overestimation of the population was 
found in 35% (7/20) of the BIAs; median = 566,67%, mean difference = 573,28%. 
The main factors that could inﬂ uence differences between predictions and actual 
spending were: underestimated (65%) or overestimated (35%) number of patients 
eligible for treatment, overestimated (30%) or underestimated (25%) market share, 
wrong assumption on 100% compliance (15%). CONCLUSION: The study has dem-
onstrated large variances between predicted budget impact and actual expenditures on 
drugs. It also revealed signiﬁ cant weaknesses in the quality of submitted BIAs, e.g.: errors 
in calculations, very limited data provided by manufacturer that unable to complete revi-
sion and reproduce of ﬁ gures in the calculation.
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As they are currently used thresholds for cost per QALY may provide a disincentive 
for companies to invest in research for therapies that prolong life in conditions with 
an already high treatment cost. Cost per QALY thresholds, although not the sole basis 
for decision making are a major inﬂ uence on whether a technology is considered 
cost-effective by NICE. Discussions have centred on the most appropriate threshold 
level and how its value should be determined. However a consequence of cost per 
QALY thresholds that is not discussed is the impact they may have on future health 
care research. The cost per QALY for renal dialysis has been estimated at £30,0001, 
the higher end of what NICE considers acceptable. We have therefore reached the 
ceiling for the cost of treating renal disease. Assuming that utility is not improved a 
treatment that extends life will be at additional cost and have a cost per QALY greater 
than £30,000. Manufacturers of health care technologies may consider that the risk 
of not getting a product approved on cost-effectiveness grounds is not worth the 
ﬁ nancial investment in its development. As health care costs continue to grow the 
management costs of more conditions will exceed £20,000 per year and future 
research may be stiﬂ ed as manufacturers seek to develop products that replace rather 
than add to current treatments. Since the background treatment cost would cancel out 
in an incremental analysis a treatment could be more cost-effective than the one it 
replaces but perversely can still be at an increased cost which raises the cost per QALY 
of standard treatment above £20,000 or £30,000. As treatment costs for more condi-
tions increase to threshold values (even if they are raised) manufactures may be advised 
to consider realigning their portfolio and investment to other diseases.
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OBJECTIVES: The objective of the CRRéa study is to assess the real daily cost of a 
patient’s stay in ICU in France. We present here preliminary results regarding the 
average time spent per patient by different health caregivers. METHODS: A prospec-
tive multicentric health economic study was performed in 23 ICUs of different French 
hospitals randomly selected from the PMSI database (French National Hospital data-
base). In a one day study, 5 adult patients were randomly selected among patients 
with a simpliﬁ ed severity score ≥ 15 in each ICU. Data on all the resources used, 
treatments administered, biological tests performed, etc. and time spent by different 
health caregiver to take care of each patient over a 24 hour period (direct and indirect 
interventions) were collected through a time and motion analysis method involving 
the professionals themselves. RESULTS: A total of 109 patients (median age = 66 
years, 65% males) of 22 intensive care units (15 polyvalent, 3 surgical and 4 medical 
ICUs) were included. 104 of them were followed over 24 hours (there were 2 deaths 
and 3 early withdrawals). On the day of the study, 84% of patients were mechanically 
